Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharyn D Baker

Showing results (131-140 of 166) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2013
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine gliomaAlberto Broniscer, Sharyn D Baker, Cynthia Wetmore, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemiaHiroto Inaba, Jeffrey E Rubnitz, Elaine Coustan-Smith, et al.
Cancer Research Communications|August 29, 2024
Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow ScreenThomas Drabison, Mike Boeckman, Yan Yang, et al.
Nature|March 11, 2011
CREBBP mutations in relapsed acute lymphoblastic leukaemiaCharles G Mullighan, Jinghui Zhang, Lawryn H Kasper, et al.
Journal of Hematology & Oncology|January 30, 2020
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemiaOla A Elgamal, Abeera Mehmood, Jae Yoon Jeon, et al.
Nature Communications|May 18, 2019
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AMLChristina D Drenberg, Anang Shelat, Jinjun Dang, et al.
Kidney International|September 17, 2021
Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibitionYuntao Bai, Ji Young Kim, Bijay Bisunke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Factors affecting cytochrome P-450 3A activity in cancer patientsSharyn D Baker, Ron H N van Schaik, Laurent P Rivory, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2019
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor MalignanciesHiroto Inaba, John C Panetta, Stanley B Pounds, et al.
Pageof 17

Showing results (131-140 of 166) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 29, 2013
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine gliomaAlberto Broniscer, Sharyn D Baker, Cynthia Wetmore, et al.
Clinical Pharmacology and Therapeutics|August 8, 2006
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner, Herman Burger, Ron H van Schaik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemiaHiroto Inaba, Jeffrey E Rubnitz, Elaine Coustan-Smith, et al.
Cancer Research Communications|August 29, 2024
Systematic Evaluation of Tyrosine Kinase Inhibitors as OATP1B1 Substrates Using a Competitive Counterflow ScreenThomas Drabison, Mike Boeckman, Yan Yang, et al.
Nature|March 11, 2011
CREBBP mutations in relapsed acute lymphoblastic leukaemiaCharles G Mullighan, Jinghui Zhang, Lawryn H Kasper, et al.
Journal of Hematology & Oncology|January 30, 2020
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemiaOla A Elgamal, Abeera Mehmood, Jae Yoon Jeon, et al.
Nature Communications|May 18, 2019
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AMLChristina D Drenberg, Anang Shelat, Jinjun Dang, et al.
Kidney International|September 17, 2021
Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibitionYuntao Bai, Ji Young Kim, Bijay Bisunke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Factors affecting cytochrome P-450 3A activity in cancer patientsSharyn D Baker, Ron H N van Schaik, Laurent P Rivory, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 29, 2019
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor MalignanciesHiroto Inaba, John C Panetta, Stanley B Pounds, et al.
Pageof 17